.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
McKinsey
Colorcon
Teva
Fish and Richardson
Healthtrust
Express Scripts
Dow
US Army
Cipla

Generated: January 17, 2018

DrugPatentWatch Database Preview

Patents Expiring in July 2020

« Back to Dashboard

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Optnose UsXHANCEfluticasone propionateSPRAY, METERED;NASAL209022-001Sep 18, 2017RXYesYes➤ Subscribe➤ SubscribeY
Bayer HlthcareAVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINERmoxifloxacin hydrochlorideSOLUTION;IV (INFUSION)021277-001Nov 30, 2001APRXYesYes➤ Subscribe➤ SubscribeYMETHOD OF COMBATING BACTERIA IN A PATIENT
DuchesnayOSPHENAospemifeneTABLET;ORAL203505-001Feb 26, 2013RXYesYes➤ Subscribe➤ SubscribeTREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
DuchesnayOSPHENAospemifeneTABLET;ORAL203505-001Feb 26, 2013RXYesYes➤ Subscribe➤ SubscribeTREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
Pharmacia And UpjohnCLEOCINclindamycin phosphateSUPPOSITORY;VAGINAL050767-001Aug 13, 1999RXYesYes➤ Subscribe➤ SubscribeY
Astrazeneca PharmsTUDORZA PRESSAIRaclidinium bromidePOWDER, METERED;INHALATION202450-001Jul 23, 2012RXYesYes➤ Subscribe➤ SubscribeYYTREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS
TheratechnologiesEGRIFTAtesamorelin acetatePOWDER;SUBCUTANEOUS022505-002Nov 29, 2011DISCNNoNo➤ Subscribe➤ SubscribeREDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY
TheratechnologiesEGRIFTAtesamorelin acetatePOWDER;SUBCUTANEOUS022505-001Nov 10, 2010RXYesYes➤ Subscribe➤ SubscribeREDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY
Sanofi-aventis UsSOLIQUA 100/33insulin glargine; lixisenatideSOLUTION;SUBCUTANEOUS208673-001Nov 21, 2016RXYesYes➤ Subscribe➤ SubscribeYY
Sanofi-aventis UsADLYXINlixisenatideSOLUTION;SUBCUTANEOUS208471-002Jul 27, 2016RXYesYes➤ Subscribe➤ SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Citi
Medtronic
McKinsey
Cantor Fitzgerald
Johnson and Johnson
Deloitte
Covington
Julphar
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot